Landos Biopharma, Inc. (LABP) Social Stream
LANDOS BIOPHARMA INC (LABP) Price Targets From Analysts
Use the tables below to see what analysts covering LANDOS BIOPHARMA INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-20 | 6 | $50 | $15 | $32.833 | $4.17 | 687.36% |
| 2021-11-16 | 6 | $50 | $15 | $30 | $4.17 | 619.42% |
| 2022-01-03 | 6 | $50 | $7 | $28.666 | $4.17 | 587.43% |
| 2022-03-24 | 6 | $50 | $7 | $26.166 | $4.17 | 527.48% |
| 2022-04-12 | 6 | $50 | $1.4 | $21.4 | $4.17 | 413.19% |
| 2022-05-12 | 6 | $50 | $0.8 | $24.16 | $4.17 | 479.38% |
| 2022-05-13 | 6 | $50 | $0.8 | $18.2 | $4.17 | 336.45% |
| 2022-08-12 | 5 | $50 | $0.8 | $17.933 | $4.17 | 330.05% |
| 2022-11-11 | 3 | $2 | $0.2 | $1.1 | $4.17 | -73.62% |
| 2023-02-08 | 3 | $2 | $0.1 | $1.05 | $4.17 | -74.82% |
| 2023-03-24 | 2 | $2 | $0.1 | $1.05 | $4.17 | -74.82% |
| 2023-05-12 | 1 | $10 | $10 | $10 | $4.17 | 139.81% |
| 2023-05-16 | 2 | $1 | $0.1 | $0.55 | $4.17 | -86.81% |
| 2023-11-09 | 1 | $5 | $5 | $5 | $4.17 | 19.9% |
Price Target Last Issued May 12, 2023
The Trend in the Analyst Price Target
Over the past 32 months, LABP's average price target has gone down $23.33.
LABP reports an average of 673.57% for its upside potential over the past 44 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-06 | 3 | 2 | 0.1 | 1.05 | 0.405 | 159.26% |
| 2023-02-08 | 3 | 2 | 0.1 | 1.05 | 0.385 | 172.73% |
| 2023-05-12 | 2 | 1 | 0.1 | 0.55 | 0.298 | 84.56% |
| 2023-05-16 | 2 | 10 | 1.0 | 5.50 | 2.905 | 89.33% |
| 2023-05-16 | 2 | 1 | 0.1 | 0.55 | 0.290 | 89.66% |
LABP Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 3 | 0 | 0 | 1 | 0 | 0 | 1 |
The Trend in the Broker Recommendations
LABP's average broker recommendation rating worsened by 1 over the prior 20 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, LANDOS BIOPHARMA INC's variance in analysts' estimates is lower than -1921.33% of them.
- In the context of all US stocks, LANDOS BIOPHARMA INC's upside potential (average analyst target price relative to current price) is greater than 1376.93% of them.
- LABP has a higher number of analysts covering the stock than 481.96% of Healthcare stocks.
- LABP has a greater average analyst price target than 885.12% of stocks in the small market cap category.
Stocks similar to LANDOS BIOPHARMA INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are TERN, SNSE, and PHVS.
View All Top Stocks by Price Target
Is LABP a Buy, Hold or Sell? See the POWR Ratings now!